Building a Robust Paperless Laboratory – Integrated Quality Approach
Presenter: Vipul Doshi, President - Group Quality Assurance and Regulatory
Mr. Vipul Doshi is the President - Group Quality Assurance and Regulatory at Zydus Cadila. He is an accomplished pharmaceutical professional serving the Pharmaceutical Industry from more than three decades.
He has led the Quality and Regulatory affairs function in various Pharma Companies of high credentials. Throughout his career he has provided passionate global leadership and pioneered in guiding the company to meet the Global Regulatory, Quality Standards and Compliance requirements.
He is a leading advocate for Global Competitiveness and instrumental in due diligence for various acquisitions and mergers. He possesses great expertise in Projects and Engineering for developing Infrastructures for APIs and Drug Products (Sterile and Non-Sterile). He is actively involved with various professional associations like ISPE/PDA/AAM.
Contributing through various roles and increasing responsibilities, he is currently President - Group Quality Assurance and Regulatory at Cadila Healthcare Ltd (Company has headquarters at Ahmedabad). He also leads Research & Development functions for Active Pharmaceutical Ingredient, Environment Health & Safety, and Pharmacovigilance.
The dream of digitalization starts with meticulous planning. Pharma companies must chart this journey keeping in mind all the stages and departments that need to be in place to realize the goal. There are tremendous benefits to digitalizing not just the lab, but also related departments. Digital data generates information that is truly useful, which can help in solid decision-making and increase the company’s potential. This exercise requires an integrated approach to quality. Pharma companies may start with QC but must gradually extend digitalization to the other related departments to create a strong foundation for enhanced quality.
Mr. Vipul Doshi, President – Global Corporate Quality takes us through the digitalization journey of Zydus Cadila, which lifted their operations to become one of the most respected pharma companies, with immense scalability and productivity capabilities.
Cadila Healthcare Limited (Zydus Cadila) is an innovative, global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs nearly 25,000 people worldwide and is dedicated to creating healthier communities globally.
The Product portfolio ranges from Complex generics Sterile and Non-Sterile, Biologics and Vaccines and various dosage forms catering to global market. It is one of the 2 largest manufacturers of a key Covid drug, Hydrochloroquine Sulphate. Currently Zydus Cadila is working towards vaccine development for Covid-19.